Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 4Thromboembolism 2Carcinoma, Non-Small-Cell Lung 2Venous Thrombosis 1Venous Thromboembolism 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pulmonary Embolism 1Prostatic Neoplasms 1Hemorrhage 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Etoposide 156Carboplatin 146Cisplatin 106Topotecan 76durvalumab 52atezolizumab 51Irinotecan 45pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 25Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Dalteparin × Thoracic × Clear all
NCT00003674 2016-07-13

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
141 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡